Monitoring Patients on Repatha (Evolocumab) Injections
Monitor LDL-cholesterol levels as the primary parameter, assess for hypersensitivity reactions (particularly injection site reactions and rare but serious angioedema), and evaluate for muscle-related symptoms, though routine laboratory monitoring beyond lipids is not required.
LDL-Cholesterol Monitoring
The most critical parameter to monitor is LDL-C levels to assess therapeutic efficacy. 1
- Timing of first assessment: LDL-C can be measured as early as 4 weeks after initiation
- For monthly dosing (420 mg): Measure LDL-C just prior to the next scheduled dose, as levels can vary during the dosing interval in some patients
- Frequency: Assess LDL-C "when clinically appropriate" per FDA labeling—typically at 4-12 weeks initially, then periodically to ensure therapeutic goals are met 1
- For HoFH patients: If clinically meaningful response is not achieved at 12 weeks on 420 mg monthly, consider dose escalation to 420 mg every 2 weeks 1
The 2022 ACC guidelines confirm that evolocumab reduces LDL-C by approximately 58-64% when added to statin therapy, making lipid monitoring essential to document efficacy 2
Hypersensitivity Reactions
Actively monitor for hypersensitivity reactions, which represent the most serious safety concern.
Injection Site Reactions (Common)
- Occur more frequently with evolocumab than placebo (2.1% vs 1.6%) 3
- Include redness, pain, or bruising at injection sites 2
- Generally mild and self-limited 4
Serious Hypersensitivity (Rare but Critical)
- Angioedema: Can be life-threatening and may require airway intervention 5
- Typically occurs within 24-48 hours of administration 5
- Action required: If serious hypersensitivity occurs, discontinue therapy immediately, treat according to standard of care, and monitor until symptoms resolve 2
- Patients should be educated to seek immediate medical attention for symptoms including trouble breathing/swallowing, raised bumps (hives), rash, itching, or swelling of face/lips/tongue/throat 1
Latex Sensitivity Consideration
- Some presentations contain dry natural rubber (latex derivative) in needle covers 1
- The on-body infusor does not contain latex 1
- Prescribe latex-free presentations for latex-sensitive patients 2
Clinical Symptoms Assessment
Muscle-Related Symptoms
- Monitor for: Myalgia, muscle spasms, or pain in extremities 2
- Muscle-related adverse events occur at similar rates to placebo in clinical trials 2, 4
- No routine creatine kinase monitoring is required unless symptoms develop
- Creatine kinase elevations are infrequent and similar between evolocumab and control groups 4
Neurocognitive Symptoms
- Neurocognitive events are infrequent (0.9% in open-label extension vs 0.3% control) 4
- No evidence of increased cognitive adverse effects in major trials (FOURIER, EBBINGHAUS) 2
- Ask about memory problems or confusion, but routine cognitive testing is not indicated
Common Non-Serious Adverse Events
Monitor for but do not require specific intervention unless bothersome:
- Nasopharyngitis, upper respiratory tract infections
- Flu-like symptoms
- Back pain
- In ASCVD patients: noncardiac chest pain 2
Laboratory Monitoring
Routine laboratory monitoring beyond lipids is NOT required based on the safety profile established in clinical trials. 4
- Liver function tests: Not routinely needed; transaminase elevations are infrequent and similar to placebo 4
- Renal function: Not routinely required; no significant renal safety signals 4
- Creatine kinase: Only if muscle symptoms develop 4
- Glucose monitoring: Continue standard diabetes monitoring if applicable; no specific evolocumab-related glucose monitoring needed
Cardiovascular Outcomes Monitoring
While not specific "monitoring," document cardiovascular events as evolocumab reduces:
- Major adverse cardiovascular events (MACE) by approximately 15-20% 3, 6
- Myocardial infarction, stroke, and coronary revascularization 2, 3
- Cardiovascular and all-cause mortality 6
Special Populations
Patients on Lipid Apheresis
- Administer evolocumab after apheresis is complete 1
- Monitor acute LDL-C reductions and calculate interval means using the Kroon formula 7
Pediatric Patients (≥10 years with HeFH or HoFH)
- Same monitoring approach as adults 1
Key Clinical Pitfalls to Avoid
- Don't measure LDL-C mid-cycle on monthly dosing: This can be misleading due to variability; measure just before next dose 1
- Don't dismiss injection site reactions: While usually benign, they may indicate developing hypersensitivity
- Don't delay airway assessment: If facial/tongue swelling occurs, this is a medical emergency requiring immediate intervention 5
- Don't stop monitoring after initial response: Continue periodic LDL-C assessment to ensure sustained efficacy
- Don't order unnecessary labs: Routine hepatic, renal, or CK monitoring adds no value without clinical indication 4